Back

Cardioprotection by selective SGLT2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury: a class or a drug effect?

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Myocardial ischaemia and protective mechanisms Ischaemia, Infarction, Cardioprotection ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Panagiota Efstathia Nikolaou

National & Kapodistrian University of Athens, Athens (Greece)

4 More presentations in this session

Presentation thumbnail
FYCO1 ameliorates adverse cardiac remodeling in response to myocardial ischemia by enhancing autophagic flux
Miss F. Senger (Heidelberg, DE)
Abstract Slides Video
Presentation thumbnail
Impaired Cardioprotection by HDL in CAD and Diabetes in Ischemia/Reperfusion Injury: role of S1P and SR-BI
Doctor A. Polzin (Duesseldorf, DE)
Abstract Slides Video
Presentation thumbnail
Systemic GDF11 replenishment ignites myocardial injury through diminishing anti-apoptotic activity of cardiac progenitor cells
Doctor S. Kraler (Bern, CH)
Abstract Slides Video
Presentation thumbnail
Erythrocytes from patients with ST-elevation myocardial infarction induce cardioprotection via the purinergic P2Y13 receptor and nitric oxide signalling
Doctor T. JIAO (Stockholm, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Myocardial ischaemia and protective mechanisms

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Mechanistic insights of SGLT2 inhibitors effectiveness
thumbnail
Congress Presentation
Potential cardio-protective role of dapagliflozin in diabetic patients presented with anterior ST-elevation myocardial infarction (STEMI).
thumbnail
Congress Presentation
Empagliflozin treatment pre- and post- acute myocardial infarction reduces no-reflow, inflammatory cell infiltration and infarct size while preserving cardiac function.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources